NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 984 DKK | +1.10% |
|
+6.11% | +40.95% |
| Jun. 06 | Novo Nordisk braces for Ozempic rivals in China | RE |
| Jun. 06 | European equities gain on tech boost in run-up to ECB | RE |
ETFs positioned on Novo Nordisk A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 218 M€ | +18.70% | ||
| 10.45% | 4 M€ | +15.27% | ||
| 5.40% | 21 M€ | +8.41% | - | |
| 4.67% | 88 M€ | +10.37% | - | |
| 3.95% | 4 M€ | -.--% | - | |
| 3.91% | 5 M€ | +10.09% | - | |
| 3.91% | 14 M€ | +5.66% | - | |
| 3.78% | 6 M€ | -.--% | ||
| 3.09% | 12 M€ | +15.09% | - | |
| 3.02% | 6 M€ | -.--% | - | |
| 2.87% | 29 M€ | +8.37% | - | |
| 2.53% | 3,859 M€ | +18.82% | - | |
| 2.53% | 469 M€ | -2.05% | ||
| 2.22% | 3 M€ | +9.95% | - | |
| 1.91% | 2 M€ | -.--% | - | |
| 1.91% | 2 M€ | +9.19% | - | |
| 1.67% | 10 M€ | -3.35% | - | |
| 1.60% | 10 M€ | +6.14% | - | |
| 1.31% | 252 M€ | +7.82% | ||
| 1.30% | 51 M€ | +8.41% | ||
| 1.21% | 17 M€ | 0.00% | ||
| 1.04% | 276 M€ | +11.40% | - | |
| 1.03% | 7 M€ | +5.53% | - | |
| 0.89% | 1,056 M€ | +4.18% | ||
| 0.79% | 284 M€ | -.--% | ||
| 0.76% | 786 M€ | -.--% | ||
| 0.76% | 23 M€ | -.--% | - | |
| 0.75% | 206 M€ | -.--% | ||
| 0.70% | 7 M€ | +0.11% | - | |
| 0.64% | 261 M€ | -.--% | - | |
| 0.64% | 200 M€ | +11.72% | - | |
| 0.64% | 488 M€ | +14.46% | ||
| 0.57% | 749 M€ | +8.64% | ||
| 0.56% | 1,166 M€ | +0.26% | - |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.95% | 632B | |
| +45.82% | 765B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| -0.78% | 219B | |
| +11.88% | 216B | |
| +5.90% | 164B | |
| -0.73% | 162B |
- Stock Market
- Equities
- NOVO B Stock
- Funds and ETFs Novo Nordisk A/S
